Literature DB >> 8565142

Activation of tamoxifen and its metabolite alpha-hydroxytamoxifen to DNA-binding products: comparisons between human, rat and mouse hepatocytes.

D H Phillips1, P L Carmichael, A Hewer, K J Cole, I R Hardcastle, G K Poon, A Keogh, A J Strain.   

Abstract

The metabolic activation of tamoxifen and its metabolite alpha-hydroxytamoxifen in primary cultures of rat, mouse and human hepatocytes has been compared. The extent of formation of DNA adducts in these cells was measured by 32P-postlabelling, using either nuclease P1 digestion or sorbent extraction of DNA digests to enhance the sensitivity of the assay. DNA adducts were readily detected in rat hepatocytes treated with 1 or 10 microM tamoxifen (mean levels 18.2 and 89.8 adducts/10(8) nucleotides respectively). Similar levels of adducts were formed by mouse hepatocytes (15.0 +/- 1.8 adducts/10(8) nucleotides, 10 microM tamoxifen). However DNA adducts were not detected in tamoxifen-treated human hepatocytes with a detection limit for the assay of 4 adducts/10(10) nucleotides. Treatment of rat cells with alpha-hydroxytamoxifen resulted in 15- to 63-fold higher levels of adducts than with comparable concentrations of tamoxifen. A similar level of adducts was also seen in mouse hepatocytes treated with alpha-hydroxytamoxifen at the 1 microM concentration (173.9 +/- 4.1 adducts/10(8) nucleotides). Treatment of human cells with alpha-hydroxytamoxifen resulted in DNA adduct formation at levels (1.94 +/- 0.89 and 18.9 +/- 17.9 adducts/10(8) nucleotides at 1 and 10 microM respectively) approximately 300-fold lower than those in rat hepatocytes. The presence of alpha-hydroxytamoxifen in the culture medium from experiments where cells were incubated with tamoxifen was monitored by mass spectrometry. Concentrations were found to be approximately 50-fold lower in the medium from human hepatocytes than from rat and mouse hepatocytes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8565142     DOI: 10.1093/carcin/17.1.89

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  4 in total

Review 1.  Clinical pharmacology of selective estrogen receptor modulators.

Authors:  B Haynes; M Dowsett
Journal:  Drugs Aging       Date:  1999-05       Impact factor: 3.923

Review 2.  The multifaceted roles of mass spectrometric analysis in nucleic acids drug discovery and development.

Authors:  Thomas Kenderdine; Dan Fabris
Journal:  Mass Spectrom Rev       Date:  2021-12-23       Impact factor: 9.011

Review 3.  New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer.

Authors:  V Craig Jordan
Journal:  Steroids       Date:  2007-07-27       Impact factor: 2.668

4.  Mutagenicity of tamoxifen DNA adducts in human endometrial cells and in silico prediction of p53 mutation hotspots.

Authors:  Evagelos Liapis; Keith I E McLuckie; Paul D Lewis; Peter B Farmer; Karen Brown
Journal:  Nucleic Acids Res       Date:  2008-09-19       Impact factor: 16.971

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.